Best Commercial Research Services Stocks by Growth Stability
5 Commercial Research Services stocks ranked by Steady Score — the proprietary growth stability rating based on 10 years of financial data.
Data as of 2026-08-01
Top stock: Medpace Holdings, Inc. (MEDP) with Steady Score 75.4.
This industry runs the outsourced research infrastructure that pharmaceutical and biotech companies rely on: contract research organizations that manage clinical trials (IQVIA, Medpace), a preclinical research and lab-animal supplier (Charles River Laboratories), and a biopharmaceutical company built on genomics-based drug discovery (Incyte).
The CRO business model itself is fee-for-service work under multi-year contracts, so it earns steady revenue regardless of which specific drugs succeed in trials, decoupling it from the binary win-or-lose economics of the biotech companies it serves. That said, the whole industry still rises and falls with the broader level of pharma and biotech R&D spending, so a sustained pullback in drug-development budgets is the main risk to watch.
- Stocks
- 5
- Avg Steady Score
- 57.0
- High stability (score ≥ 75)
- 1
- Avg Revenue CAGR
- +12.6%
Of the 5 Commercial Research Services stocks, 1 (20%) have high growth stability (Steady Score ≥ 75). The industry average Steady Score is 57.0, with average annualized revenue growth of +12.6% and earnings growth of +22.6%.
| Rank | Name | Steady Score |
|---|---|---|
| 1 | Medpace Holdings, Inc. | 75.4 |
| 2 | IQVIA HOLDINGS INC. | 59.09 |
| 3 | INCYTE CORP | 54.88 |
| 4 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 49.05 |
| 5 | NRC HEALTH | 46.61 |